BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/23/2017 11:56:00 AM | Browse: 393 | Download: 371
Publication Name World Journal of Cardiology
Manuscript ID 29448
Country/Territory United States
2016-08-15 10:25
Peer-Review Started
2016-08-16 08:54
To Make the First Decision
2016-09-05 09:21
Return for Revision
2016-09-06 09:20
2016-10-31 00:00
Second Decision
2016-11-29 09:52
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2016-12-09 17:28
Articles in Press
2016-12-09 17:28
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2017-02-20 13:22
Publish the Manuscript Online
2017-02-23 11:56
ISSN 1949-8462 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Cardiac and Cardiovascular Systems
Manuscript Type Review
Article Title PCSK9 inhibitors: A new era of lipid lowering therapy
Manuscript Source Invited Manuscript
All Author List Rahul Chaudhary, Jalaj Garg, Neeraj Shah and Andrew Sumner
Funding Agency and Grant Number
Corresponding author Jalaj Garg, MD, FESC, Division of Cardiology, Lehigh Valley Health Network, 1250 S Cedar Crest Blvd, Allentown, PA 18103, United States. garg.jalaj@yahoo.com
Key Words Hyperlipidemia; Statins; Proprotein convertase subtilsin-kexin type 9
Core Tip Hyperlipidemia is a well-established risk factor for developing cardiovascular disease (CVD). However, there are limited options for patients who are either intolerant to statin therapy, develop CVD despite being on maximally tolerated statin therapy, or have severe hypercholesterolemia. The Food and Drug Administration has approved two novel medications for low-density lipoprotein (LDL)-cholesterol reduction in this patient population: Evolocumab and Alirocumab. These agents target and inactivate proprotein convertase subtilsin-kexin type 9 (PCSK9), a hepatic protease that attaches and internalizes LDL receptors into lysosomes hence promoting their destruction. By preventing LDL receptor destruction, LDL-C levels can be lowered 50%-60% above that achieved by statin therapy alone. PCSK9 inhibitors are an exciting agent for reducing LDL-C and have ushered in a new era of lipid lowering therapy.
Publish Date 2017-02-23 11:56
Citation Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol 2017; 9(2): 76-91
Url http://www.wjgnet.com/1949-8462/full/v9/i2/76.htm
DOI http://dx.doi.org/10.4330/wjc.v9.i2.76
Full Article (PDF) WJC-9-76.pdf
Full Article (Word) WJC-9-76.doc
Manuscript File 29448-Review.doc
Answering Reviewers 29448-Answering reviewers.pdf
Audio Core Tip 29448-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 29448-Conflict-of-interest statement.pdf
Copyright License Agreement 29448-Copyright assignment.pdf
Peer-review Report 29448-Peer-review(s).pdf
Scientific Misconduct Check 29448-Scientific misconduct check.pdf
Scientific Editor Work List 29448-Scientific editor work list.pdf